PANK1 and pantothenate kinase-associated neurodegeneration: For example, the failure of the PPan derivative fosmetpantotenate as a replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN) creates the need for alternative molecules to raise intracellular CoA levels in such diseases47,48.